Viviana Simon
#21,209
Most Influential Person Now
Microbiologist and researcher
Viviana Simon's AcademicInfluence.com Rankings
Viviana Simonbiology Degrees
Biology
#3416
World Rank
#5229
Historical Rank
Microbiology
#448
World Rank
#504
Historical Rank
Neuroscience
#2244
World Rank
#2305
Historical Rank
Download Badge
Biology
Viviana Simon's Degrees
- PhD Microbiology University of California, Berkeley
- Masters Biology Stanford University
- Bachelors Biotechnology University of California, Berkeley
Similar Degrees You Can Earn
Why Is Viviana Simon Influential?
(Suggest an Edit or Addition)According to Wikipedia, Viviana Simon is a Professor of Microbiology at the Icahn School of Medicine at Mount Sinai . She is a member of the ISMMS Global Health and Emerging Pathogens Institute. Her research considers viral-host interactions and the mode of action of retroviral restriction factors. During the COVID-19 pandemic, Simon developed an antibody test that can determine immunity to Coronavirus disease 2019.
Viviana Simon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection (2021) (1934)
- Identification of microRNAs of the herpesvirus family (2005) (1229)
- A serological assay to detect SARS-CoV-2 seroconversion in humans (2020) (1067)
- Robust neutralizing antibodies to SARS-CoV-2 infection persist for months (2020) (939)
- A serological assay to detect SARS-CoV-2 seroconversion in humans (2020) (879)
- HIV/AIDS epidemiology, pathogenesis, prevention, and treatment (2006) (614)
- SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup (2020) (594)
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine (2021) (590)
- DENV Inhibits Type I IFN Production in Infected Cells by Cleaving Human STING (2012) (413)
- Introductions and early spread of SARS-CoV-2 in the New York City area (2020) (366)
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron (2021) (312)
- Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification (2005) (275)
- Serology assays to manage COVID-19 (2020) (267)
- SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters (2022) (267)
- SARS-CoV-2 spike E484K mutation reduces antibody neutralisation (2021) (253)
- Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection (2017) (252)
- Intrinsic host restrictions to HIV-1 and mechanisms of viral escape (2015) (237)
- SAMHD1-Deficient CD14+ Cells from Individuals with Aicardi-Goutières Syndrome Are Highly Susceptible to HIV-1 Infection (2011) (235)
- Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis (2011) (203)
- Tracking the Prevalence of Transmitted Antiretroviral Drug-Resistant HIV-1: A Decade of Experience (2006) (192)
- Dengue Virus Co-opts UBR4 to Degrade STAT2 and Antagonize Type I Interferon Signaling (2013) (184)
- HIV-1 dynamics in vivo: implications for therapy (2003) (178)
- SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 (2021) (167)
- Cytidine deamination induced HIV-1 drug resistance (2008) (166)
- Polymorphisms and Splice Variants Influence the Antiretroviral Activity of Human APOBEC3H (2008) (161)
- Origin of the HIV-1 group O epidemic in western lowland gorillas (2015) (155)
- Immunological memory to SARS-CoV-2 assessed for up to eight months after infection (2020) (152)
- Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. (2002) (151)
- Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma (2021) (143)
- An In Vitro Microneutralization Assay for SARS‐CoV‐2 Serology and Drug Screening (2020) (141)
- Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals (2002) (140)
- A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells. (2016) (133)
- Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine (2021) (129)
- Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study (2020) (128)
- Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication (2004) (127)
- HIV-1 Vpu Antagonism of Tetherin Inhibits Antibody-Dependent Cellular Cytotoxic Responses by Natural Killer Cells (2014) (121)
- The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. (2021) (116)
- Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City (2020) (114)
- Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection. (2016) (103)
- Reducing the global burden of HTLV‐1 infection: An agenda for research and action (2017) (102)
- The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera (2021) (102)
- Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants (2022) (99)
- BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. (2015) (96)
- Determining the relative efficacy of highly active antiretroviral therapy. (2003) (93)
- Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques. (2006) (92)
- The Activity Spectrum of Vif from Multiple HIV-1 Subtypes against APOBEC3G, APOBEC3F, and APOBEC3H (2011) (92)
- Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region (2020) (91)
- Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals (2003) (90)
- HIV-1 Vif adaptation to human APOBEC3H haplotypes. (2013) (90)
- APOBEC3A, APOBEC3B, and APOBEC3H Haplotype 2 Restrict Human T-Lymphotropic Virus Type 1 (2012) (88)
- A Doubly Fluorescent HIV-1 Reporter Shows that the Majority of Integrated HIV-1 Is Latent Shortly after Infection (2013) (82)
- Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission (2022) (73)
- Vif Proteins of Human and Simian Immunodeficiency Viruses Require Cellular CBFβ To Degrade APOBEC3 Restriction Factors (2011) (68)
- Origin of Human Immunodeficiency Virus Type 1 Quasispecies Emerging after Antiretroviral Treatment Interruption in Patients with Therapeutic Failure (2002) (65)
- Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model (2018) (64)
- The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters (2021) (62)
- Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals (2010) (62)
- Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2 (2020) (58)
- Defining the risk of SARS-CoV-2 variants on immune protection (2022) (58)
- Infectivity and Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 Variants Isolated during Primary Infection (2003) (57)
- Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection (2004) (53)
- Surveillance of European Domestic Pig Populations Identifies an Emerging Reservoir of Potentially Zoonotic Swine Influenza A Viruses. (2020) (52)
- The Localization of APOBEC3H Variants in HIV-1 Virions Determines Their Antiviral Activity (2010) (51)
- Moderate Influence of Human APOBEC3F on HIV-1 Replication in Primary Lymphocytes (2010) (51)
- Identification of the HIV-1 Vif and Human APOBEC3G Protein Interface. (2015) (50)
- SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors (2021) (49)
- APOBEC3G Polymorphism as a Selective Barrier to Cross-Species Transmission and Emergence of Pathogenic SIV and AIDS in a Primate Host (2013) (49)
- Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City (2020) (47)
- Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma (2021) (46)
- Immune mechanisms of HIV control. (2010) (42)
- HIV-1 Interacts with Human Endogenous Retrovirus K (HML-2) Envelopes Derived from Human Primary Lymphocytes (2014) (42)
- Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance (2018) (42)
- COVID-19: Staging of a New Disease (2020) (41)
- The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD (2021) (41)
- Mapping SARS-CoV-2 antigenic relationships and serological responses (2022) (40)
- Vif Proteins from Diverse Primate Lentiviral Lineages Use the Same Binding Site in APOBEC3G (2013) (39)
- IL-15 regulates susceptibility of CD4+ T cells to HIV infection (2018) (39)
- Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron (2021) (37)
- HIV protease cleaves the antiviral m6A reader protein YTHDF3 in the viral particle (2020) (34)
- mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations (2022) (33)
- The Resistance of Human APOBEC3H to HIV-1 NL4-3 Molecular Clone Is Determined by a Single Amino Acid in Vif (2013) (32)
- Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFκB (2014) (31)
- Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients (2021) (31)
- Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective. (2020) (29)
- Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate (2021) (28)
- Balancing Selection on a Regulatory Region Exhibiting Ancient Variation That Predates Human–Neandertal Divergence (2013) (28)
- The arrival and spread of SARS‐CoV‐2 in Colombia (2020) (27)
- Genetic Basis of Hypersusceptibility to Protease Inhibitors and Low Replicative Capacity of Human Immunodeficiency Virus Type 1 Strains in Primary Infection (2004) (27)
- Tumor Suppressor Cylindromatosis (CYLD) Controls HIV Transcription in an NF-κB-Dependent Manner (2014) (26)
- Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant (2022) (24)
- HIV Vpu Interferes with NF-κB Activity but Not with Interferon Regulatory Factor 3 (2015) (24)
- SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals (2022) (24)
- Characterization of HIV-1 integrase N-terminal mutant viruses. (2007) (23)
- Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice (2018) (23)
- Expression of HERV-K108 envelope interferes with HIV-1 production. (2017) (23)
- Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay. (2020) (22)
- Evidence for a (π-allyl)palladium intermediate in the quinone-based palladium-catalysed allylic acetoxylation (1994) (22)
- The Structural Interface between HIV-1 Vif and Human APOBEC3H (2016) (21)
- Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37 (2021) (20)
- Identification and functional analysis of a second RBF-2 binding site within the HIV-1 promoter. (2011) (20)
- Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans (2018) (20)
- Efficient mucosal antibody response to SARS-CoV-2 vaccination is induced in previously infected individuals (2021) (20)
- HIV-1 Infection of Primary CD4+ T Cells Regulates the Expression of Specific Human Endogenous Retrovirus HERV-K (HML-2) Elements (2017) (19)
- Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif (2015) (19)
- Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients (2022) (19)
- Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals (2021) (16)
- SARS-CoV-2 spread across the Colombian-Venezuelan border (2020) (16)
- A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2 (2020) (16)
- Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial (2022) (16)
- Predictors of treatment failure during highly active antiretroviral therapy (racing trial). (2002) (15)
- Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection In Vitro and in a Mouse Model (2018) (15)
- SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage (2021) (15)
- Functional characterization of Vif proteins from HIV-1 infected patients with different APOBEC3G haplotypes (2016) (14)
- Positive Regulation of TRAF6-Dependent Innate Immune Responses by Protein Phosphatase PP1-γ (2014) (13)
- Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. (2017) (12)
- FACS-Mediated Isolation of Neuronal Cell Populations From Virus-Infected Human Embryonic Stem Cell-Derived Cerebral Organoid Cultures. (2018) (12)
- Characterization of swine-origin H1N1 canine influenza viruses (2019) (12)
- A HIGH THROUGH-PUT ASSAY FOR CIRCULATING ANTIBODIES DIRECTED AGAINST THE S PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) (2020) (11)
- Human Monoclonal Antibodies Potently Neutralize Zika Virus and Select for Escape Mutations on the Lateral Ridge of the Envelope Protein (2019) (11)
- Dose-Dependent Differences in HIV Inhibition by Different Interferon Alpha Subtypes While Having Overall Similar Biologic Effects (2019) (11)
- Synthesis of New Thiazolidinone Nucleoside Analogues (1995) (10)
- Molecular evidence of SARS-CoV-2 in New York before the first pandemic wave (2021) (10)
- Impact of Suboptimal APOBEC3G Neutralization on the Emergence of HIV Drug Resistance in Humanized Mice (2019) (9)
- Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera (2022) (9)
- Intrahost evolution and forward transmission of a novel SARS-CoV-2 Omicron BA.1 subvariant (2022) (9)
- Identification and Characterization of Novel Antibody Epitopes on the N2 Neuraminidase (2021) (8)
- Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice (2021) (7)
- Functionality of the putative surface glycoproteins of the Wuhan spiny eel influenza virus (2021) (7)
- Robust clinical detection of SARS‐CoV‐2 variants by RT‐PCR/MALDI‐TOF multitarget approach (2021) (7)
- Real Time Investigation of a large Nosocomial Influenza A Outbreak Informed by Genomic Epidemiology (2020) (7)
- Proceedings of the Frontiers of Retrovirology Conference 2016 (2016) (7)
- Evaluation and validation of an RT‐PCR assay for specific detection of monkeypox virus (MPXV) (2022) (6)
- Longitudinal analysis of SARS-CoV-2 seroprevalence using multiple serology platforms (2021) (6)
- Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants (2022) (6)
- Deciphering the introduction and transmission of SARS-CoV-2 in the Colombian Amazon Basin (2021) (6)
- Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes (2021) (6)
- Detection of Antibody Responses against SARS-CoV-2 in Plasma and Saliva from Vaccinated and Infected Individuals (2021) (5)
- PARIS and SPARTA: Finding the Achilles’ Heel of SARS-CoV-2 (2022) (5)
- Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer (2022) (5)
- Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants (2022) (5)
- Novel Epitopes of the Influenza Virus N1 Neuraminidase Targeted by Human Monoclonal Antibodies (2022) (5)
- Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms (2021) (4)
- Virology under the Microscope—a Call for Rational Discourse (2023) (4)
- Human Anti-neuraminidase Antibodies Reduce Airborne Transmission of Clinical Influenza Virus Isolates in the Guinea Pig Model (2021) (4)
- The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility (2016) (4)
- Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients (2021) (4)
- Positive, again! What to make of “re-positive” SARS-CoV-2 molecular test results (2020) (4)
- Hotspots for SARS‐CoV‐2 Omicron variant spread: Lessons from New York City (2022) (4)
- Peptide-Nucleoside Conjugates: Synthesis and Anti-HIV Activities (1995) (4)
- The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization (2022) (3)
- Reply to Hasenkrug et al., “Different Biological Activities of Specific Interferon Alpha Subtypes” (2019) (3)
- Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis (2022) (3)
- Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies (2022) (3)
- ISG15 deficiency restricts HIV-1 infection (2022) (3)
- Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain (2022) (3)
- Novel epitopes of human monoclonal antibodies targeting the influenza virus N1 neuraminidase (2021) (2)
- Before the Surge: Molecular Evidence of SARS-CoV-2 in New York City Prior to the First Report (2021) (2)
- Structure of a germline-like human antibody defines a neutralizing epitope on the SARS-CoV-2 spike NTD (2021) (2)
- Robust clinical detection of SARS-CoV-2 variants by RT-PCR/MALDI-TOF multi-target approach (2021) (2)
- Synthesis of New Thiazolidinone Nucleoside Analogues. (1995) (2)
- Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines (2022) (2)
- A Robust, Highly Multiplexed Mass Spectrometry Assay to Identify SARS-CoV-2 Variants (2022) (1)
- SARS-CoV-2 in Transit: Characterization of SARS-CoV-2 Genomes From Venezuelan Migrants in Colombia (2021) (1)
- SARS-CoV-2 variants of concern have acquired mutations associated with an 1 increased spike cleavage 2 (2021) (1)
- SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with antigenically similar SARS-CoV-2 variants (2022) (1)
- Profiling Selective Packaging of Host RNA and Viral RNA Modification in SARS-CoV-2 Viral Preparations (2022) (1)
- Virology under the Microscope—a Call for Rational Discourse (2023) (1)
- Virology under the Microscope—a Call for Rational Discourse (2023) (1)
- Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment (2021) (1)
- The T cell receptor repertoire reflects the dynamics of the immune response to vaccination (2021) (1)
- A robust, highly multiplexed mass spectrometry assay to identify SARS-CoV-2 variants (2022) (1)
- Sustained viremia during highly active antiretroviral therapy with accelerated proviral DNA decay in the setting of infection with syphilis. (2003) (1)
- RT-PCR/MALDI-TOF Diagnostic Target Performance Reflects Circulating SARS-CoV-2 Variant Diversity in New York City (2021) (1)
- Contribution of APOBEC3-Driven Mutagenesis to HIV Evolution and HIV Drug Resistance (2014) (1)
- Transmission of Drug-Resistant HIV (2008) (1)
- Whole-Genome Sequencing: The Key to Unlocking a Nosocomial Outbreak of Coronavirus Disease 2019 (COVID-19) (2021) (1)
- NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine (2021) (1)
- RT-PCR and Matrix-Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry Diagnostic Target Performance Re fl ects Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Variant Diversity in New York City (0)
- Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model (2018) (0)
- Phylogenetic landscape of Monkeypox Virus (MPV) during the early outbreak in New York City, 2022. (2023) (0)
- An Influenza Virus Hemagglutinin-Based Vaccine Platform Enables the Generation of Epitope Specific Human Cytomegalovirus Antibodies (2019) (0)
- SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants (2022) (0)
- Bivalent COVID-19 booster vaccines induce cross-reactive but not BA.5-specific antibodies in polyclonal serum (2023) (0)
- Proceedings of the Frontiers of Retrovirology Conference 2016 (2016) (0)
- Mpox vaccine and infection-driven human immune signatures (2023) (0)
- Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants (2023) (0)
- Title : SARS-CoV-2 variants of concern have acquired mutations associated with an 1 increased spike cleavage 2 3 (2021) (0)
- Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients (2022) (0)
- Heterogeneity of Latency Establishment in the Different Human CD4+ T Cell Subsets Stimulated with IL-15 (2022) (0)
- Binding and avidity signatures of polyclonal sera from individuals with different exposure histories to SARS-CoV-2 infection, vaccination, and Omicron breakthrough infections. (2023) (0)
- Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination (2022) (0)
- Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site (2022) (0)
- Synthesis and Preliminary Characterization of Modified 45s5 Bioglasses (2020) (0)
- Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City (2020) (0)
- Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFκB (2014) (0)
- An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination (2023) (0)
- from Human Primary Lymphocytes Retrovirus K ( HML-2 ) Envelopes Derived HIV-1 Interacts with Human Endogenous (2014) (0)
- Development of an HIV reporter virus that identifies latently infected CD4+ T cells (2022) (0)
- Protection Against Influenza B Viruses by Human Monoclonal Antibodies that Target the Neuraminidase Active Site (2020) (0)
- BIRC 2 / cIAP 1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency Graphical (0)
- Abstract 798: SeroNet Pooling Project of immunocompromised populations (2023) (0)
- Murine Broadly Reactive Antineuraminidase Monoclonal Antibodies Protect Mice from Recent Influenza B Virus Isolates and Partially Inhibit Virus Transmission in the Guinea Pig Model (2022) (0)
- Jeroen Primary Infection Virus Type 1 Variants Isolated during Drug-Resistant Human Immunodeficiency Infectivity and Replication Capacity of (2003) (0)
- Polymorphisms and Splice Variants Influence the Antiretroviral Activity of Human APOBEC3H (cid:1) (0)
- Identification of the HIV-1 Vif and Human APOBEC 3 G Protein Interface Graphical Abstract Highlights (0)
- BIRC2/cIAP1 Suppresses HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency (2015) (0)
- OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment (2021) (0)
- tRNA abundance, modification and fragmentation in nasopharyngeal swabs as biomarkers for COVID-19 severity (2022) (0)
- Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies (2023) (0)
- One-year results of the retrovirus-activity-comparing-trial (1999) (0)
- The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility (2016) (0)
- The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines (2022) (0)
- Antigenic Landscape Analysis of Individuals Vaccinated with a Universal Influenza Virus Vaccine Candidate Reveals Induction of Cross-Subtype Immunity (2022) (0)
- Activity of human serum antibodies in a hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay (2020) (0)
- Fundamentals of HIV biology (2020) (0)
This paper list is powered by the following services:
Other Resources About Viviana Simon
What Schools Are Affiliated With Viviana Simon?
Viviana Simon is affiliated with the following schools:
